Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | CLPP | Q16740 | 2/20 | 0.45 |
| ▸ | CCR3 | P51677 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502894 | 0.89 | ACHE (0.60) | ACHE | |
| SCHEMBL4491399 | 0.86 | OPRM1 (0.49) | OPRM1ACHEKMT2ASIGMAR1MEN1 | |
| SCHEMBL4500070 | 0.85 | CXCR4 (0.53) | OPRM1ACHEATM | |
| SCHEMBL4499874 | 0.81 | DCPS (0.45) | OPRM1ACHEKMT2ASIGMAR1MEN1 | |
| SCHEMBL4502250 | 0.81 | ACHE (0.48) | OPRM1ACHEKMT2ASIGMAR1MEN1 | |
| SCHEMBL4503813 | 0.79 | PARP1 (0.54) | KMT2ASIGMAR1MEN1CCR3 | |
| SCHEMBL4502362 | 0.77 | CACNA1G (0.45) | OPRM1KMT2ASIGMAR1MEN1CCR3 | |
| SCHEMBL4502368 | 0.76 | OPRM1 (0.40) | OPRM1ACHEKMT2ASIGMAR1MEN1 | |
| SCHEMBL4516525 | 0.76 | TP53 (0.49) | OPRM1KMT2ASIGMAR1MEN1CCR3 | |
| SCHEMBL4503740 | 0.75 | PDGFRB (0.56) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | OPRM1 388/4885ACHE 4551/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.